Personalized medicine in CLL: Current status and future perspectives

Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The pre...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2014-09, Vol.352 (1), p.4-14
Main Authors: Rozovski, Uri, Hazan-Halevy, Inbal, Keating, Michael J, Estrov, Zeev
Format: Article
Language:English
Subjects:
Chromosomes
CLL
Decision making
Drug therapy
Hematology, Oncology and Palliative Medicine
Humans
Immunotherapy - trends
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Mutation
Personalized medicine
Precision medicine
Precision Medicine - standards
Precision Medicine - trends
Targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • While CLL is still considered an incurable disease, the clinical course is extremely variable. Therefore, an individualized approach is needed. • Cytogenetic studies including FISH provide valuable prognostic information and are recommended in all newly diagnosed CLL patients. • The presence of somatic mutations in IGHV, expression of ZAP-70 or CD38, and serum levels of β2M, or thymidine kinase are also of prognostic value. • Several tyrosine kinase inhibitors currently being investigated in CLL induce responses in patients with chemotherapy-refractory disease. • In the future, integrated clinical and genetic information will guide personalized, curative therapy.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2013.07.013